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Abstract: Although the correlation between polyunsaturated fatty acids (PUFA) and the production of
pro- and anti-inflammatory metabolites is well documented, little is known about the simultaneous
effect of different PUFA on the production of cyclooxygenase and lipoxygenase metabolites. The present
research examines the association between different omega-3 (ω-3) and omega-6 (ω-6) PUFA and the
release of four cyclooxygenase and six lipoxygenase metabolites in cell medium by human umbilical
vein endothelial cells (HUVEC). The different combinations of ω-3 and ω-6 PUFA were prepared
according to a full 24 factorial design that enables studying not only the main effects but also the
different interactions between fatty acids. In addition, interactions diagrams and principal component
analysis were useful tools for interpreting higher order interactions. To the best of our knowledge, this is
the first report addressing the combined effect ofω-3 andω-6 PUFA on the signaling of prostaglandins,
prostacyclins, leukotrienes and resolvins by HUVEC.
Keywords: polyunsaturated fatty acids; docosahexaenoic acid; eicosapentaenoic acid; α-linolenic acid;
arachidonic acid; human umbilical vein endothelial cells; eicosanoids; prostacyclins; leukotrienes; resolvins
1. Introduction
Since the publication of the articles by Dyerberg and collaborators in the early seventies on the
low incidence of heart disease in Greenland Eskimos [1,2], there has been a growing interest in the
nutritional and pharmaceutical properties of polyunsaturated fatty acids (PUFA), especially those of
the omega-3 (ω-3) family. Studies on the beneficial effects of ω-3 PUFA and the detrimental effects
omega-6 (ω-6) PUFA on humans have been carried out extensively.
Long chainω-3 PUFA including α-linolenic acid (18:3ω-3, ALA), eicosapentaenoic acid (20:5ω-3,
EPA), docosapentaenoic acid (22:5ω-3, DPA) and docosahexaenoic acid (22:6ω-3, DHA) are a
group of compounds possessing anti-inflammatory and immunomodulatory properties. They have
demonstrated to be beneficial to cardiac [3,4], musculoskeletal [5], gastrointestinal [6] and immune
systems in humans [7,8].
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One of the most important functions of PUFA is related to their enzymatic conversion into
eicosanoids. PUFA are released from membrane phospholipids by the action of various phospholipases
and metabolized to different eicosanoids. Arachidonic acid (20:4ω-6, ARA) is the substrate for
two classes of enzymes, cyclooxygenases (COX) which produce the 2-series of prostaglandins,
prostacyclins and thromboxanes, and lipoxygenases (LOX) which catalyze the biosynthesis of
hydroxyeicosatetraenoic acids (HETE) and the 4-series leukotrienes. EPA exhibits a similar metabolism
to ARA, but it is metabolized to the 3-series prostaglandins, prostacyclins and thromboxanes through
the action of the COX enzymes and 5-series leukotrienes and hydroxyeicosapentaenoic acids (HEPE)
from LOX. DHA is mainly converted to D-series resolvins by LOX. The metabolism of PUFA is shown
in Figure 1.
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Figure 1. Metabolism of different ω-3 and ω-6 PUFA. EPA and ARA compete for the
same cyclooxygenase (COX) and lipoxygenase (LOX) enzymes and they are converted into
prostaglandins, prostacyclins and thromboxanes by COX enzymes and into leukotrienes, lipoxins,
hydroxyeicosatetraenoic acids by different LOX enzymes. DHA produces the anti-inflammatory
resolvins D (RvD) through the action of LOX enzymes (5-LOX and 15-LOX). The studied PUFA and
metabolites in the present research are indicated by blue and red stars, respectively.
Studies on human cancer cells have indicated that ω-3 (e.g., EPA, DHA) and also ω-6 (e.g., ARA)
PUFA are actively incorporated into endothelial cells and interconverted to anti- and pro-inflammatory
mediators, such as eicosanoids, leukotrienes and resolvins, through the action of the COX (cyclic
pathway) and LOX (linear pathway) enzymes [9,10]. These studies have also revealed that high levels
ofω-6 PUFA in the Western diets is one of t e main factors responsible for many maladies, including
cardiovascular, cancer, autoimmune and inflammatory diseases [11–17], whileω-3 fatty acids exert
suppressive effects [18,19].
The majority of re orted studies are focused on evaluating particular fatty acids from specific
famili s (either ω-3 or ω-6 PUFA). However, it is equally important to assess in which extent the
interactions between different PUFA affect th production of COX and LOX metabolites. Unfortunately,
such studies are still relatively scarce, partly due to their inherent multifactorial character and their
susceptibility to confounding factors that in turn might unveil correlations between variables when
there is not actually a correlation [20]. For instance, nutritional studies on the effect of ω-3 PUFA
generally use marine oils as a source of EPA and DHA to induce significant beneficial variations on
different experimental groups. These variations might be the result of confounding factors, considering
for example that marine oils are also rich in vitamin D.
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Confounding factors may contribute to inconsistent or conflicting results as reported in studies
on the production of inflammatory mediators by salmon and cod head kidney cells supplemented
withω-3 PUFA [21,22] or in human plasma from patients exposed to an anti-inflammatory treatment
of salmon and vitamin D [23] where it was observed that ω-3 PUFA increases the production of
inflammatory eicosanoids rather than decreasing it. This puzzling finding was rationalized as the
incorporation of exogenous ω-3 PUFA at the expense of releasing endogenous ω-6 PUFA from the
cell membrane which in turn is converted into inflammatory eicosanoids. This example highlights
the significance and complexity of confounding variables and the importance of scrutinizing the
conclusions derived from nutritional studies, especially those claiming that a specific diet component
will cause or prevent certain diseases.
Human umbilical vein endothelial cells (HUVEC) can be regarded as a valuable tool for studying
different biological aspects of endothelial cells. Their availability, easy to isolate in a pure form, low
cost, rapid culturing and proliferation in simple laboratory settings (e.g., medium containing fetal
bovine serum) made them a very attractive system for modelling the influence of ω-3 and ω-6 PUFA
on the production of their associated pro- and anti-inflammatory biomarkers through the cyclic (COX
enzyme) and linear (LOX enzyme) pathways.
Published studies on the production of eicosanoids in cell culture systems supplemented with
ω-3 andω-6 PUFA are generally focused on the effect of individual PUFA in a univariate way without
considering the potential effect of their interactions on eicosanoid production [24,25].
The present research aims at studying the production of cyclooxygenase and lipoxygenase
metabolites by HUVEC exposed to different combinations of PUFA. The research assesses specifically
the levels of prostaglandins (PGE2, PGE3), prostacyclins (6-keto-PGF1α, ∆17-6-keto-PGF1α), resolvins
(RvD1, RvD2, RvD3, RvD4 and 17-epi-RvD1) and leukotriene (LTB4) released into endothelial cell
growth basal medium-2 (EBM-2) by HUVEC exposed to ARA, EPA, DHA and ALA, 18:3n-3 by means
of a full factorial design and a previously developed solid phase extraction and liquid chromatography
tandem mass spectrometry (SPE-LC-MS/MS) method [26]. Through this research, it was observed the
inhibitory effect of DHA and ALA on the production of pro-inflammatory COX metabolites, the lack
of correlation between EPA and production of anti-inflammatory prostaglandin or prostacyclin, the
association between ARA and increased production of all pro-inflammatory metabolites, and the
enhanced production of LOX metabolites by DHA. To our knowledge, the present research is the
first report addressing the influence of single and combinedω-3 andω-6 PUFA on the simultaneous
production of eicosanoids and resolvins’ metabolites by HUVEC.
2. Materials and Methods
2.1. Reagents
Prostaglandins: PGE2 (99%), PGE3 (98%); prostacyclins: 6-keto-PGF1α (98%), ∆17-6-keto-PGF1α
(98%); leukotriene: LTB4, (97%); resolvins: RvD1 (95%), RvD2 (95%), RvD3 (95%), RvD4 (95%), RvD5
(95%) and deuterated internal standards: PGE2-d4 (99%), 6-keto-PGF1α-d4 (99%), LTB4-d4 (97%) and
RvD2-d5 (95%) were purchased from Cayman Chemical (Ann Arbor, MI, USA).
Acetonitrile (99.8%), ethanol (99.8%) acetic acid (99%) and formic acid (98%) were purchased
from Sigma-Aldrich (St. Louis, MO, USA), 2-propanol (HPLC grade, 99.9%) from Merck (Darmstadt,
Germany), a Millipore Milli-Q system was used to produce ultra-pure water 18 MΩ (Millipore, Milford,
MA, USA). EPA (99%), ARA (95%), DHA (98%) and ALA (99%) were from Sigma-Aldrich (Oslo,
Norway). Complete EBM-2 contained EBMTM-2 basal medium supplemented with 0.1% heparin, 0.1%
R3-IGF−1 solution, 0.1% ascorbic acid, 0.04% hydrocortisone, 0.4% h-FGF-B, 0.1% h-EGF, 0.1% GA−1000
and 2% fetal bovine serum (FBS, cat# 14-801F) was from BioWhittaker (Petit Rechain, Belgium).
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2.2. Cell Culture
The HUVEC were bought from Sigma-Aldrich and incubated in culture plates with complete
EBM-2 medium supplemented with 0.1% heparin, 0.1% R3-IGF−1 solution, 0.1% ascorbic acid, 0.04%
hydrocortisone, 0.4% h-FGF-B, 0.1% h-EGF, 0.1% GA−1000 and 2% FBS. Fifteen PUFA ethanolic
solutions, suggested by the factorial design (Table 1), were prepared at a level of concentration of
6.1 M of each fatty acid. Aliquots of 15 µL were taken from every solution by attaching the fatty
acids to FBS at a ratio of 2:1 for 18 h at room temperature and diluting with EMB-2 medium to a
final a concentration of 46 µM of fatty acid. A blank solution was made by adding FBS and ethanol
(the solvent used to dissolve the fatty acids) and diluting with EMB-2 medium. Once the number of
cells reached 105 cells/well, the medium was removed and the EMB-2 solutions containing EPA, ARA,
DHA and ALA were added according to a 24-full factorial design (Table 1). Cultures were prepared in
triplicate (16 × 3) and incubated at 37 ◦C in humidified atmosphere of 95% air and 5% CO2. After 24 h,
the supernatants were collected and stored at –80 ◦C until extraction.
2.3. Extraction and Quantitative Measuring of Cyclooxygenase and Lipoxygenase Metabolites
The SPE protocol and LC-MS/MS quantification were based on a previous published method [26].
Briefly, an aliquot of 100 µL of a mixture of internal standards (180 ng/mL PGE2-d4, 45 ng/mL
6-keto-PGF1α-d4, 40 ng/mL RvD2-d5 and 30 ng/mL LTB4-d4) was added to 1 mL of sample. Ethanol
(175 µL) and acetic acid (20 µL) were added and the mixture was vortex-mixed and applied to a SPE
column (Agilent, ASPEC Bond Elute C18, 500 mg, 3 mL, Santa Clara, CA, USA) which had been
preconditioned with 2 mL of methanol and 2 mL of water. The cartridge was washed with 4 mL
of distilled water and 4 mL of hexane to remove peptides and salts as well as polar and nonpolar
interfering substance. The analytes were eluted with 1 mL of hexane/ethyl acetate (1:2 v/v), collected
into a glass tube and the solvent was evaporated under a stream of nitrogen gas. The dried sample was
redissolved in 70 µL of acetonitrile, vortex-mixed 30 s, centrifuged at 1620 g for 3 min and transferred to
an auto sampler vial for LC-MS/MS quantitative analysis by using electro spray ionization in negative
mode. The quantification was carried out by using the internal standard calibration technique described
elsewhere [26] by dissolving PGE2, PGE3, 6-keto-PGF1α, ∆17-6-keto-PGF1α, LTB4, RvD1, 17-epi-RvD1,
RvD2, RvD3 and RvD4 in complete EBM-2 medium and adding the internal standards at the above
indicated concentration levels. The analysis of the extracted ion chromatograms of the analytical
species revealed that the characteristic mass fragmentation patterns were clearly distinguished from
each other, indicating that the analysis was selective towards deuterated and non-deuterated analytes.
2.4. Statistics
To evaluate the main effects and their interactions, multifactor ANOVA was performed to determine
whether or not there are significant differences between the means of the analysed metabolites with
or without the fatty acids and the significance established by means of F-ratios and expressed as
p-values by using Statgraphics Centurion XVI (Version 16.1.11, StatPoint Technologies, Inc., Warrenton,
VA, USA). Tukey’s test was employed as correction procedure for multiple testing. The interactions
between two factors were analysed by means of interaction diagrams described elsewhere [27,28].
The results were submitted to principal component analysis (PCA) in order to detect meaningful
relationships between the high order interactions and highlight differences and similarities in the data
set by using Statistica™ (data analysis software system) version 13.4.0.14, TIBCO Software Inc. (2018).
3. Results
The released PGE2, PGE3, 6-keto-PGF1α, ∆17-6-keto-PGF1α, LTB4, RvD1, 17-epi-RvD1, RvD2,
RvD3 and RvD4 into EBM-2 by HUVEC after exposure to single or combined DHA, EPA, ALA and
ARA and by using the described 24-full factorial design are shown in Table 1 as average values of
three independent replicates (individual data are presented in Table S1). The term CODE in Table 1
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is used to summarize the various conditions dictated by the design. For example, ALL as a code
indicates the presence of DHA, EPA, ALA and ARA (condition +1, +1, +1, +1, respectively), while
ALL-DHA indicates the absence of DHA and the presence of EPA, ALA and ARA (condition −1, +1,
+1, +1, respectively).
3.1. Main Effects Evaluation
The effect of the main terms were analysed by computing the average values of every metabolite
without (−1) and with (+1) PUFA (Table 2) and their significance expressed as p-values (Figures 2–4
and Table S2).
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combinations. The asterisks indicate significa t values at p < 0.05 (*), p < 0.001 (**) and p < 0.000 (***).
The actual numerical p-values are described in Table S2.
e presence of DHA (+1 level) caused a statistically significant decrease in the production of pro-
and anti-inflamm tory prostaglandins and prostacyclins (PGE2, 6-keto-PGF1α, ∆17-6-keto-PGF1α and
PGE3) and significant increase in the production of pr - and ti-inflammatory metabolites from
the LOX pathway (leukotriene and resolvins) (Table 2, Figures 2–4 and Table S2). The ig est and
lowest decrease in production were exhibited by PGE2 (73%) and PGE3 (33%) respectively, while RvD4
(1673%), 17epi-RvD1 (1522%) and RvD1 (1278%) showed remarkable increases in production.
The addition of EPA did not affect the production of the prostaglandins and prostacyclins (Figure 1)
but LTB4 that was increased in 60% (Figure 3, Table 2). The results after exposing HUVEC to EPA
(Table 2, Figures 3 and 4) are characterized by significant increases in LTB4 (60%; p < 0.000) and RvD2
(30%; p = 0.002) and significant decreases (p < 0.000) in 17epi-RvD1 (29%) and RvD4 (21%). The rest of
the resolvins (RvD1 and RvD3) production did not change after exposure to EPA.
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Table 1. A 24-full factorial design to assess the release of prostaglandins (PGE2, PGE3), prostacyclins (6-keto-PGF1α, ∆17-6-keto-PGF1α), leukotriene (LTB4)
and resolvins (RvD1, 17epi-RvD1, RvD2, RvD, RvD4) into endothelial cell growth basal medium-2 (EBM-2) by HUVEC after exposure to the following PUFA:
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), α-linolenic acid (ALA) and arachidonic acid (ARA). The absence or presence of each fatty acid is designated
as −1 and +1, respectively. The amount of metabolite in picograms (pg) is expressed as average ± standard error of three independent culture preparation replicates
(n = 3). The values were computed by using the individual measurements in Table S1.
CODE
PUFA Metabolites
ω-3 ω-6 Cyclooxygenase Pathway Lipoxygenase Pathway
DHA EPA ALA ARA PGE2 PGE3 6-keto-PGF1α ∆17-6-keto-PGF1α LTB4 RvD1 17epi-RvD1 RvD2 RvD3 RvD4
ALL +1 +1 +1 +1 76.1 ± 5.0 51.9 ± 1.7 75.6 ± 4.3 175.5 ± 12.4 197.2 ± 7.7 27.6 ± 1.9 17.6 ± 0.8 5.8 ± 0.4 5.4 ± 0.4 95.9 ± 5.4
ALL-ARA +1 +1 +1 −1 5.7 ± 0.2 14.3 ± 0.7 13.4 ± 0.5 69.7 ± 5.2 104.2 ± 3.5 15.0 ± 1.1 20 ± 1.5 1.5 ± 0.1 1.6 ± 0.1 11.7 ± 0.5
ALL-ALA * +1 +1 −1 +1 90.4 ± 5.2 70.4 ± 7.8 33.8 ± 3.6 123.5 ± 9.6 116.6 ± 4.0 14.9 ± 0.2 24.8 ± 1.3 3.4 ± 0.1 4.5 ± 0.1 48.6 ± 0.5
DHA+EPA +1 +1 −1 −1 5.6 ± 0.2 15.6 ± 1.0 7.9 ± 0.5 17.5 ± 1.1 44.8 ± 3.0 19.0 ± 0.9 2.1 ± 0.1 12.2 ± 0.7 6.7 ± 0.1 36.2 ± 1.5
ALL-EPA +1 −1 +1 +1 119.7 ± 2.5 60.8 ± 4.3 42.7 ± 2.8 154.1 ± 3.4 186.0 ± 4.7 16.3 ± 1 32.7 ± 0.8 6.7 ± 0.3 2.7 ± 0.1 70.5 ± 1.4
DHA+ALA +1 −1 +1 −1 3.3 ± 0.1 7.0 ± 0.2 16.5 ± 0.9 50.8 ± 4.1 36.9 ± 1.2 16.7 ± 0.5 14.1 ± 1.0 1.9 ± 0.1 8.2 ± 0.6 56.4 ± 1.5
DHA+ARA +1 −1 −1 +1 24.5 ± 1.4 64 ± 3.7 25.1 ± 0.2 149.4 ± 6.5 65.2 ± 1.9 33.2 ± 1.5 34.7 ± 1.8 6.4 ± 0.4 5.5 ± 0.4 61.7 ± 2.1
DHA +1 −1 −1 −1 4.2 ± 0.3 7.9 ± 0.6 13.2 ± 0.5 29.2 ± 2.2 14.3 ± 1.1 16.4 ± 1 11.8 ± 0.8 1.9 ± 0.1 5.8 ± 0.5 45.3 ± 1.4
ALL-DHA −1 +1 +1 +1 184.9 ± 3.0 58.5 ± 0.8 83.3 ± 3.9 198.3 ± 1.0 58.8 ± 0.9 2.8 ± 0.2 0.0 ± 0.0 0.7 ± 0.0 1.6 ± 0.1 0.0 ± 0.0
EPA+ALA −1 +1 +1 −1 6.8 ± 0.5 17.5 ± 0.6 32.8 ± 0.5 77.1 ± 5.8 29.3 ± 2.0 0.0 ± 0.0 0.3 ± 0.0 0.9 ± 0.0 1.7 ± 0.1 1.3 ± 0.1
EPA+ARA −1 +1 −1 +1 397.3 ± 4.9 111.9 ± 6.3 59.3 ± 1.7 473.4 ± 33.9 75.1 ± 1.9 1.5 ± 0.1 0.5 ± 0.0 0.7 ± 0.0 1.6 ± 0.1 3.9 ± 0.1
EPA −1 +1 −1 −1 7.8 ± 0.2 20.8 ± 1.4 23.6 ± 1.5 37.2 ± 2.4 22.8 ± 0.8 3.7 ± 0.3 4.4 ± 0.1 0.7 ± 0.0 0.6 ± 0.0 1.6 ± 0.1
ALA+ARA −1 −1 +1 +1 244.2 ± 7.6 78.6 ± 6.2 57.6 ± 2.6 113 ± 2.3 53.5 ± 0.7 1.3 ± 0.1 0.0 ± 0.0 0.7 ± 0.0 0.7 ± 0.0 2.3 ± 0.1
ALA −1 −1 +1 −1 7.5 ± 0.2 7.4 ± 0.5 30.2 ± 0.8 41.7 ± 2.6 15.5 ± 1.2 2.2 ± 0.1 2.5 ± 0.1 1.2 ± 0.1 0.7 ± 0.0 1.2 ± 0.1
ARA −1 −1 −1 +1 359.7 ± 10.6 130.8 ± 5.4 100.3 ± 6 617.3 ± 28.6 29.9 ± 1.4 0.0 ± 0.0 1.9 ± 0.2 1.1 ± 0.0 2.3 ± 0.2 3.4 ± 0.1
EtOH −1 −1 −1 −1 4.2 ± 0.3 7.6 ± 0.6 8.4 ± 0.6 34.5 ± 0.5 3.6 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.0 10.5 ± 0.6
The term CODE summarizes the various conditions dictated by the factorial design. For example, ALL is the condition where the four PUFAs are added into the medium (the four PUFA
at level + 1), while ALL-DHA is the condition where EPA, ALA and ARA are at level +1 and DHA was not added (level −1). * Only duplicate preparations were available for ALL-ALA (n = 2).
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Table 2. Average production of prostaglandins, prostacyclins, leukotriene and resolvins by HUVEC exposed to different PUFA. The values used to compute the
averages at level −1 and +1 are those described in Table S1. Values in picograms (pg) are expressed as average ± standard error.
Prostaglandins Prostacyclins Leukotriene Resolvins
PUFA Level PGE2 PGE3 6-keto-PGF1α ∆17-6-keto-PGF1α LTB4 RvD1 17epi-RvD1 RvD2 RvD3 RvD4
DHA
−1 151.6 ± 2.4 54.1 ± 2.0 49.4 ± 1.5 199.1 ± 7.5 36.1 ± 1.7 1.4 ± 0.5 1.2 ± 0.5 0.8 ± 0.2 1.3 ± 0.2 3.0 ± 1.0
+1 41.2 ± 2.5 36.5 ± 2.0 28.5 ± 1.6 96.2 ± 7.7 95.7 ± 1.8 19.9 ± 0.5 19.7 ± 0.5 5.0 ± 0.2 5.1 ± 0.2 53.3 ± 1.0
EPA
−1 95.9 ± 2.4 45.5 ± 2.0 36.8 ± 1.5 148.8 ± 7.5 50.6 ± 1.7 10.8 ± 0.5 12.2 ± 0.5 2.5 ± 0.2 3.3 ± 0.2 31.4 ± 1.0
+1 96.8 ± 2.5 45.1 ± 2.0 41.2 ± 1.6 146.6 ± 7.7 81.1 ± 1.8 10.6 ± 0.5 8.7 ± 0.50.5 3.3 ± 0.2 3.0 ± 0.2 24.9 ± 1.0
ALA
−1 111.7 ± 2.5 53.6 ± 2.0 34.0 ± 1.6 185.3 ± 7.7 46.5 ± 1.8 11.1 ± 0.5 10.1 ± 0.5 3.3 ± 0.2 3.5 ± 0.2 26.4 ± 1.0
+1 81.0 ± 2.4 37.0 ± 2.0 44.0 ± 1.5 110.0 ± 7.5 85.2 ± 1.7 10.2 ± 0.5 10.9 ± 0.5 2.4 ± 0.2 2.9 ± 0.2 29.9 ± 1.0
ARA
−1 5.6 ± 2.4 12.3 ± 2.0 18.2 ± 1.5 44.7 ± 7.5 33.9 ± 1.7 9.1 ± 0.5 6.9 ± 0.5 2.6 ± 0.2 3.3 ± 0.2 20.5 ± 1.0
+1 187.1 ± 2.5 78.4 ± 2.0 59.7 ± 1.6 250.6 ± 7.7 97.8 ± 1.8 12.2 ± 0.5 14.0 ± 0.5 3.2 ± 0.2 3.1 ± 0.2 35.8 ± 1.0
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; ALA: α-linolenic acid; ARA: arachidonic acid. Level −1 without PUFA; Level +1 with PUFA.
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3.2. Interaction Effects Evaluation
Interaction diagrams (Figures 5 and 6) were used to explain the effect of the different two-term
interactions on the production of COX- and LOX-derived metabolites. The diagrams were constructed
by allocating every pair of PUFA on a two-dimensional graph with mutually perpendicular axes.
The graph was divided into four quadrants and the values in each quadrant were computed according
to the levels of the 24 factorial design as explained in Figure S1. For example, when studying the
interaction EPA and DHA, they are designated as x-axis and y-axis respectively. The intersecting
x- and y-axes divide the coordinate plane into four quadrants (Figure S1). The quadrant I (levels
+1,+1) is the average value of all the experiments containing both ω-3 PUFA (e.g., ALL, ALL-ARA,
ALL-ALA, DHA+EPA in Table 1, Figure S1), the quadrant II (levels −1, +1) is the average value of all
the experiments without EPA but containing DHA (e.g., ALL-EPA, DHA+ALA, DHA+ARA, DHA in
Table 1, Figure S1), the quadrant III (levels −1,−1) is the average value of all the experiments without
EPA or DHA (e.g., ALA+ARA, ALA, ARA, EtOH in Table 1, Figure S1) and the quadrant IV (levels
+1, −1) is the average value of all the experiments containing EPA but not DHA (e.g., ALL-DHA,
EPA+ALA, EPA+ARA, EPA in Table 1, Figure S1). The statistical significance of the interactions are
showed in Figures 2–4 and Table S2.
The interaction effect of DHA×EPA on reducing the production of inflammatory and
anti-inflammatory prostaglandins and prostacyclins by HUVEC was not significant (p > 0.05) as
indicated in Figure 2. Figure 5 shows that the initial production of PGE2 without these PUFA
(III quadrant: 153.9 ± 3.4 pg) is dramatically reduced after adding DHA (II quadrant: 37.9 ± 3.4 pg),
but it is marginally reduced after adding EPA (IV quadrant: 149.2 ± 3.4 pg). In addition, the reduction
after adding DHA and EPA (I quadrant: 44.53 ± 3.6 pg) is statistically equivalent to the effect of adding
DHA alone, hence the significance of the interaction DHA×EPA (p = 0.105) is disregarded. A similar
behavior was observed for the rest of the prostaglandins and prostacyclins when the interaction
DHA×EPA is considered (Figure 5).
The results in Figure 6 for the production of LTB4 without EPA or DHA (25.5 ± 2.5 pg) revealed a
considerable enhancement when the HUVEC were exposed either to DHA (II quadrant: 75.6 ± 2.5 pg)
or EPA (IV quadrant 46.5 ± 2.5 pg). However, their combined effect DHA×EPA results in a much
higher and significant release (I quadrant: 115.6 ± 2.6 pg).
The interaction term DHA×EPA revealed to be significant (Table S2) in decreasing the production
of 17epi-RvD1 (p = 0.000, Figure 3), RvD3 (p = 0.006, Figure 4) and RvD4 (p = 0.013, Figure 4) and
increasing the production of RvD2 (I quadrant: 5.7 pg, Figure 6) compared to DHA alone (II quadrant:
4.3 pg, Figure 6), which represent an increasing of 32.6% (Figure 3, p = 0.002). Although the effect
of the interaction DHA×EPA was not significant for RvD1 (p = 0.075), a slight tendency to decrease
(I quadrant: 19.5 pg) was observed compared to DHA alone (II quadrant: 20.6 pg).
The interaction DHA×ALA contributed in decreasing the production of all inflammatory or
anti-inflammatory prostaglandins and prostacyclins (Figure 2, Table S2) compared to the system
without these PUFA. In contrast, the interaction DHA×ARA significantly promoted the production
of all COX-derived metabolites (Figure 2). The interaction DHA×ARA played a significant role in
increasing the production of RvD1 (p < 0.000) but not DHA×ALA (p = 0.130) (Figure 3). Both interactions,
DHA×ALA and DHA×ARA, significantly enhanced the production of LTB4, 17epi-RvD1, RvD2, RvD3
and RvD4 (Figures 3 and 4).
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The interaction EPA×ALA decreased the production of PGE2 and ∆17-6-keto-PGF1α (p < 0.000),
while the production of 6-keto-PGF1α (p < 0.000) is increased (Figure 2). This particular interaction
decreased the production of all anti-inflammatory resolvins and PGE3 (p = 0.384). However, the observed
reduction was statistically significant only for RvD1 (p = 0.002) and RvD2 (p < 0.000) (Figure 3).
The interaction EPA×ARA did not affect the production of any of the analyzed pro-inflammatory
but the anti-inflammatory mediators (except for RvD1). While the interaction ALA×ARA was not
significant for 6-keto-PGF1α (p = 0.969), RvD1 (p = 0.503) and RvD3 (p = 0.211).
The most salient feature of the triple and quadruple interaction terms is that EPA×ALA×ARA
and DHA×EPA×ALA×ARA influence all the pro- and anti-inflammatory metabolites, except for PGE3
(p = 0.562) in the former and PGE2 (p = 0.523) and PGE3 (p = 0.460) in the latter.
3.3. Principal Component Analysis (PCA)
The data set (Table S1) was arranged in a m × n matrix, where m represents the experimental
conditions and n represents the different ten measured COX- and LOX-metabolites. The 50 × 10 matrix
was standardized by subtracting their means and dividing by their standard deviations. The PCA score
and loading plots, describing relationships between PUFA and between metabolites, respectively were
computed and shown in Figure 7. The score plot in Figure 7a revealed that the information retained
by PC1 and PC2 (explaining 43.38 and 34.74% of the total data variability) is mainly associated with
DHA and ARA, respectively. These PUFA allow discriminating four experimental patterns according
to their presence (+DHA or +ARA) or absence (-DHA or -ARA). A high degree of overlapping
was also observed between the various experimental conditions and biological replicates, including
the two types of controls (-EtOH and +EtOH) which might indicate a similar mechanism in the
production of the measured biomarkers. The loading plot (Figure 7b) revealed that the inverse
correlation between LOX metabolites (negative PC1 loading values) and COX metabolites (positive
PC1 loading values) is responsible for the observed discrimination patterns. The contribution of LTB4
(−0.462) in the discrimination process was lower than the resolvins, while the contribution of the
anti-inflammatory PGE3 (0.398) was lower than the inflammatory prostaglandins and prostacyclins.
The highest absolute PC1 loading values were exhibited by RvD1 (−0.896) and PGE2 (0.622) and
consequently their contribution to the discrimination process was higher than the rest of the metabolites.
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Figure 7. PCA (a) score an ( ) l t o ing the relationship between the different
combinations of ω-3 -6 PUFA according to the proposed 24 f ctor al ign described in
Table 1 and the relationship between the different COX and LOX metabolites, respectively. The plots
show that DHA and ARA are the main substrates behind the production of LOX and COX metabolites,
respectively. DHA is associated with a high production of resolvins, which is counter regulated by ARA
through a high production of prostaglandins. The loading plot confirms that 78.12% of the total data
variability is explained by the production of resolvins and prostaglandins. The numbers inside the nine
different clusters correspond to the different PUFA combinations. 1=ALL; 2=ALL-ARA; 3=ALL-ALA;
4=DHA+EPA; 5=ALL-EPA; 6=DHA+ALA; 7=DHA+ARA; 8=DHA; 9=ALL-DHA; 10=EPA+ALA;
11=EPA+ARA; 12=EPA; 13=ALA+ARA; 14=ALA; 15=ARA; 16=+EtOH; 17=-EtOH.
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4. Discussion
The multitude of potential mechanisms and the complexity of the PUFA has made it difficult to
fully understand the actions of these fatty acids within inflammatory processes. Thus, in the present
study, a full factorial design was used to study the release of pro- and anti-inflammatory lipid mediators




The findings (Figures 2–4 and Table 2) confirmed the strong relationship between addition of
exogenous DHA and increased levels of all the metabolites from the LOX pathway (especially the
resolvins) and decreased levels of all the metabolites from the COX pathway (prostaglandins and
prostacyclins). The observed inhibition of prostaglandins and prostacyclins by DHA is in agreement
with data from human umbilical cord [29] and bovine aortic [30–34] endothelial cells, respectively.
4.1.2. EPA Effect
Interestingly, we found no significant association between EPA and increased production of
anti-inflammatory PGE3 or ∆17-6-keto-PGF1α. The levels of PGE3 and PGE2 remained unaltered
after adding EPA (Table 2) that is in stark contrast to the reported competition process betweenω-3
PUFA and ARA for binding to the cyclooxygenase active site and thereby inhibit formation of the
2-series prostaglandins that are derived from ARA [35]. For instance, some studies have observed that
an increased intake of EPA suppressed the synthesis of ARA-derived eicosanoids and increased the
formation of the analogous EPA derived mediators [7,36–40]. The incorporation of EPA and release of
ARA has already been reported [41]. However, it is important to point out that this effect occurs in a
dose-response and time-dependent fashion [41,42]. The findings in the present research are similar
to those reported in previous HUVEC experiments [43], where the lower affinity of COX enzymes
for ω-3 EPA was ascribed to a low rate of EPA oxygenation by COX−1 as explained elsewhere [35].
EPA and ARA bind to the cyclooxygenase active site by positioning their C−13 below Tyr-385 for
hydrogen abstraction. The presence of an additional double bond in EPA decreases its flexibility in the
cyclooxygenase active site resulting in a strained binding orientation and a misalignment between C−13
and Tyr-385, which is presumably responsible for the low rate of EPA oxygenation and consequently
a low conversion into PGE3 [35]. The previous observations are confirmed in Figure 5, where the
simultaneous effect of EPA×ARA revealed a constant production of PGE2 regardless of the presence
of EPA (187.0 ± 3.6 pg without EPA versus 187.2 ± 3.4 pg with EPA) but a remarkable production of
PGE2 by the presence of ARA (4.8 ± 3.4 pg versus 187.0 ± 3.6 pg). Further investigation is necessary to
assess the influence of the concentration of EPA in the production of PGE3. In addition, the production
of anti-inflammatory metabolites from EPA through the LOX pathway such as LTB5 or the E-series
resolvins should be investigated to verify whether the production of these metabolites are preferred
over PGE3.
4.1.3. ALA Effect
In general, the effect of ALA brought about a considerable reduction in the production of anti- and
pro-inflammatory metabolites from the COX pathway (Figures 2 and 3, Tables 2 and S2), indicating
a possible inhibition of the COX-enzymes by the action of ALA which in turn might cause the
observed remarkable enhancement of the LOX pathway as reflected in the 83% increase in LTB4.
The inhibitory role of ALA has been reported in a study aiming at isolating compounds with COX
inhibitory activity [44].
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4.1.4. ARA Effect
The levels of all pro-inflammatory metabolites were remarkably high in all the preparations
containing ARA (Figure 2, Table 2). These results were in accordance with the well-known fact that
pro-inflammatory prostaglandins, prostacyclins and leukotriene are promoted via COX and LOX
pathways from ARA. In addition, the observed increase in both EPA (PGE3 and ∆17-6-keto-PGF1α)
and DHA (with the exception of RvD3) derived metabolites (Figures 2–4, Table 2) could indicate that,
during the incubation period of 24 h, ARA is incorporated in the cell membrane at the expense of
EPA and DHA. The incorporation of ARA into the cell membrane has been already reported by using
radioactive free ARA [45]. Furthermore, some studies have observed increased levels of LTB5 (EPA
metabolite) in skin cells from dogs fed n-6/n-3 diet ratios of 5/1 and 10/1 [46]. The amounts and types
of synthesized eicosanoids are determined by several factors, among them the availability of released
PUFA, the activity of the cyclo- or lipoxygenase and the cell type [47,48].
4.2. Two-Term Interactions
4.2.1. DHA×EPA, DHA×ALA, DHA×ARA
The interaction DHA×EPA showed a general non-significant decrease in those metabolites derived
from the COX pathway and a statistically significant increase in all the metabolite derived from the LOX
pathway (leukotriene and resolvins) with the exception of RvD1 that was not significant at the 95% but
at the 99% confidence level. This result might indicate a synergist effect between the stimulatory effect
of DHA on LOX expression and inhibitory effect on COX expression. The interactions DHA×ALA
and DHA×ARA were statistically significant for all the COX-derived metabolites. The behavior of
the former interaction was characterized by a decreased production of all the analyzed COX-derived
metabolites, while the latter exhibited a consistent increment in production of the equivalent metabolites.
The observed behavior is in accordance with the reported inhibitory effect of DHA and ALA [29,44] and
widely reported stimulatory effect of ARA on COX-2 expression. Both interactions, DHA×ALA and
DHA×ARA, showed a positive impact on the production of resolvins as a result of DHA stimulation.
4.2.2. EPA×ALA, EPA×ARA
The interaction EPA×ALA had a negative impact on PGE2 and the two EPA derived metabolites
(∆17-6-keto-PGF1α and PGE3). The production of PGE2, ∆17-6-keto-PGF1α and PGE3 is governed by
the substrates ARA and EPA and the COX enzymes. However, as explained above, EPA exhibited
a low oxygenation by COX−1, which could bring about a low production of ∆17-6-keto-PGF1α and
PGE3 [35]. In addition, some studies have demonstrated that ALA has a strong selectivity towards
COX-2, which in turn has a negative impact on the biosynthesis of PGE2 [38]. Although LTB4 and
all the analyzed resolvins from the D-series are LOX-5 catalyzed derivatives, the production rate of
LTB4 by the action of the interactions EPA×ALA and EPA×ARA was higher than those observed for
resolvins. This result might be attributed to the lack of exogenous DHA, the release of ARA from the
cell membrane after EPA incorporation [43] and the ALA COX-2 inhibitory effect [44] that promotes
the signaling of ARA through the LOX pathway.
4.2.3. ALA×ARA
In general, the interaction ALA×ARA brought about an increase in all the studied metabolites.
The positive effect of this interaction on the production of ∆17-6-keto-PGF1α and PGE3 is notable
despite the lack of exogenous EPA. Two possible mechanisms of action could explain the observed
effect. Firstly, the incorporation of ARA and further release of EPA and secondly, the biosynthesis of
EPA from ALA. It has been reported that ALA is a substrate for the synthesis of EPA, but the conversion
rates are low [49,50]. In light of the present research, it is possible to hypothesize that exogenous ALA
might contribute to enhancing the EPA production and consequently its associated COX metabolites.
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4.3. Three- and Four-Term Interactions
The triple and four term interactions containing the term ALA×ARA exhibited the highest
numbers of significant effects compared to those without this particular interaction term (Figures 2–4,
Table S2). For example, EPA×ALA×ARA was not statistically significant for PGE3 but significant
for the rest of the metabolites, DHA×ALA×ARA and DHA×EPA×ALA×ARA were not significant
for RvD1, RvD3 and PGE2, PGE3, respectively (both with eight significant effects). The interactions
DHA×EPA×ALA and DHA×EPA×ARA were not significant for PGE2, 6-keto-PGF1α, PGE3, RvD4 and
PGE2, ∆17-6-keto-PGF1α, PGE3 and RvD1 (both with six significant effects). It is remarkable that PGE3
was not significant in all three- and four-PUFA interactions containing exogenous EPA, indicating
probably its inhibitory effect on COX enzyme or the conversion of EPA to the prostanoid PGH3, which
can be isomerized to thromboxane A3 (TXA3) and PGD3 (Figure 1). The interpretation of the three-
and four-PUFA interactions is considerably more complicated, especially bearing in mind that the
behavior ofω-3 andω-6 PUFA and their derivatives in biological systems have been regarded as more
intricate than previously recognized [51]. The PCA was proposed to facilitate the interpretation process
and detect important relationships between the interactions. The PCA plots confirmed that single
ARA or that combined with EPA or ALA (e.g., ARA, EPA×ARA, ALA×ARA and EPA×ALA×ARA
in the quadrant −DHA/+ARA of Figure 7a) are consistently associated with high levels of COX
metabolites and low levels of resolvins (Figure 7b) and that the effect of the interaction EPA×ARA is
equivalent to the effect of ARA alone (Figure 7a). Conversely, replacing ARA by DHA to evaluate the
impact of the counterpart preparations DHA, DHA×EPA, DHA×ALA and DHA×EPA×ALA (quadrant
+DHA/–ARA of Figure 7a) brings about a significant reduction in the levels of COX metabolites and
an increase in the levels of LOX metabolites. The lowest levels of COX and LOX metabolites were
exhibited by preparations where DHA and ARA were not added (EPA, ALA, EPA×ALA and control
with ethanol in the quadrant –DHA/–ARA of Figure 7a) indicating probably a low affinity of the COX
and LOX enzymes towards EPA and a low rate of interconversion of ALA into EPA. The highest levels
of LOX metabolites were found in those preparations containing both DHA and ARA (DHA×ARA,
DHA×EPA×ARA, DHA×ALA×ARA and DHA×EPA×ALA×ARA in the quadrant +DHA/+ARA of
Figure 7a). The levels of LTB4 were consistently higher than the control in all the PUFA preparations.
5. Conclusions
The role of lipid mediators in human health, signaling and regulation processes is partly
determined by the specific PUFA from which the pro- or anti-inflammatory metabolites are derived.
Thus, the present research has examined the association between different ω-3 and ω-6 PUFA and
the release of ten different COX and LOX metabolites in cell culture medium by HUVEC. The present
research confirmed earlier published results on the anti-inflammatory role ofω-3 PUFA (DHA and
ALA), and the lack of effectivity of EPA towards the production of PGE3 in a HUVEC model. However,
the non-significant production of PGE3 by EPA seems to be controversial and it has been reported
previously in mammalian cell models, including HUVEC. In addition, exposing the cells to exogenous
ARA resulted in a high production of COX metabolites. The high levels of COX metabolites were
suppressed when ARA was combined with DHA, ALA or DHA×ALA. DHA enhanced all the
LOX metabolites (LTB4 and resolvins), while ALA enhanced only the levels of the LTB4 but had
no effect on resolvins. The present findings have indicated that DHA but not EPA is the driving
force behind the beneficial effects of these ω-3 PUFA and that the actions of ω-3 and ω-6 PUFA
and their derivatives on inflammatory processes involve more complex mechanisms than previously
recognized. Consequently, future investigations are necessary to access the effect of PUFA, especially
EPA, at different concentrations and in a time-dependent fashion.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/5/966/s1,
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